Abstract Number: 2599 • 2017 ACR/ARHP Annual Meeting
Efficacy and Toxicity of Antimalarials in Systematic Lupus Erythematosus: A Systematic Review
Background/Purpose: To determine the efficacy and adverse effects of antimalarials in patients with systematic lupus erythematosus (SLE). Methods: A literature search from inception to December…Abstract Number: 543 • 2017 ACR/ARHP Annual Meeting
Adverse Events in Rheumatoid Arthritis Patients Treated with Disease Modifying Biological Drugs at Hospital Docente Padre Billini in Santo Domingo
Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory autoimmune chronic disease with disability and deforms joints. After the introduction of biological therapies the prognosis of…Abstract Number: 819 • 2017 ACR/ARHP Annual Meeting
Risks of Non-Cardiovascular Corticosteroid Related Adverse Events and Cancer in Giant Cell Arteritis: A French Population-Based Cohort Study
Background/Purpose: Corticosteroid related adverse events are a main concern in patients suffering from giant cell arteritis. Conflicting results are reported on this topic, recurrent events…Abstract Number: 850 • 2017 ACR/ARHP Annual Meeting
Immune Checkpoint Inhibitors and Inflammatory Myopathies: Data from the US Food and Drug Administration Adverse Event Reporting System
Background/Purpose: Immune checkpoint inhibitors have become standard of care for many malignancies. Although these therapies are effective, they can activate the immune system resulting in…Abstract Number: 1182 • 2017 ACR/ARHP Annual Meeting
Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events
Background/Purpose: Autoantibodies (AAB) targeting self-antigens can be found in two clinically and immunologically opposing diseases, autoimmune diseases and cancer. While in autoimmune diseases, the immune…Abstract Number: 1600 • 2017 ACR/ARHP Annual Meeting
Lupus Nephritis Is Associated with Increased Rates of Hospitalization for Adverse Events on a Glucocorticoid Toxicity Index and in-Hospital Mortality Compared with Non-Renal Lupus and Matched Controls: An Analysis of Insurance Claims Data
Background/Purpose: Systemic lupus erythematosus (SLE) is heterogeneous in its clinical prognosis and lupus nephritis (LN) is a major cause of morbidity and mortality among children…Abstract Number: 1755 • 2017 ACR/ARHP Annual Meeting
Safety of Methotrexate and Low-Dose Trimethoprim-Sulfamethoxazole in Patients with ANCA-Associated Vasculitis
Background/Purpose: Low-dose trimethoprim-sulfamethoxazole (LDTS, 160mg-800mg 3x/week or 80mg-400mg/day) is effective for prevention of Pneumocystis jiroveci pneumonia (PCP), a serious opportunistic infection seen in patients with…Abstract Number: 121 • 2017 Pediatric Rheumatology Symposium
Safety Of Biological Response Modifiers In Childhood Autoimmune Rheumatic Diseases From A Single North Indian Centre
Background/Purpose: Biologic Response modifiers (BRMs) are sparingly used in India due to: cost & concern of infections. We are a tertiary level centre & have…Abstract Number: 2178 • 2016 ACR/ARHP Annual Meeting
Statin Use and Increased Risk of Musculoskeletal Conditions: A Retrospective Cohort Study with Propensity Score-Matching
Background/Purpose: Given conflicting evidence regarding statin use and the relationship with musculoskeletal conditions, and the rising disability and societal/personal repercussions associated with both osteoarthritis (OA)…Abstract Number: 2332 • 2016 ACR/ARHP Annual Meeting
Midterm Outcome of Modular Metal-on-Metal Total Hip Arthroplasty
Background/Purpose: Wear, osteolysis, and late aseptic loosening associated with ultrahigh-molecular-weight polyethylene components used in total hip arthroplasties (THA) have led to increased interest in metal-on-metal…Abstract Number: 2444 • 2016 ACR/ARHP Annual Meeting
Effects of Disease Activity and Drug Exposure on Pregnancy Outcomes with Inflammatory Arthritis
Background/Purpose: Pregnancy is often encountered in women who have inflammatory arthritis (IA), such as rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile arthritis (JIA) or ankylosing…Abstract Number: 2547 • 2016 ACR/ARHP Annual Meeting
Quantification of Adverse Glucocorticoid Effects on Skin in Rheumatoid Arthritis
Background/Purpose: Glucocorticoids (GCs) are frequently and often chronically used for the treatment of rheumatoid arthritis (RA) and other immune diseases and vasculitis. An estimated 0.8–1.2%…Abstract Number: 2595 • 2016 ACR/ARHP Annual Meeting
Real World Results from a Post-Approval Safety Surveillance of Tofacitinib (Xeljanz): Over 3 Year Results from an Ongoing US-Based Rheumatoid Arthritis Registry
Background/Purpose: An interim analysis of a prospective observational 3+ year study, embedded within the US Corrona Rheumatoid Arthritis (RA) registry (14 years and ongoing), was…Abstract Number: 2629 • 2016 ACR/ARHP Annual Meeting
Serious Adverse Events in Patients with RA Taking Abatacept Compared with Other Dmards. Results from a US-Wide Safety Registry
Background/Purpose: Observational studies are critical in assessing medication safety and effectiveness in the real world. Nonrandom assignment can provide insight to how and when medications…Abstract Number: 2970 • 2016 ACR/ARHP Annual Meeting
Incidence and Characteristics of Vasculitis Associated with Monoclonal Antibodies and Peptide Fusion Proteins: A Survey from the French National Pharmacovigilance Database
Background/Purpose: Immunological classes of adverse events (AEs), including the immune related AEs and the paradoxical effects, have emerged with the used of biologics. Among them,…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 10
- Next Page »